Skip to main content

Westshore Terminals Investment Corp(WTE-T)
TSX

Today's Change
Real-Time Last Update

Global Sequencing Reagents Market (2021 to 2028) - Featuring Agilent Technologies, BGI Genomics and Qiagen Among Others - ResearchAndMarkets.com

Business Wire - Fri Nov 19, 2021

The "Global Sequencing Reagents Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

According to this report, the global sequencing reagents market is assessed to observe a growth trend at a CAGR of 12.83% based on revenue through the considered period 2021-2028.

Companies Mentioned

  • Agilent Technologies Inc
  • Asuragen Inc
  • BGI Genomics
  • Bio Rad Laboratories Inc
  • F Hoffmann La Roche
  • Fluidigm Corporation
  • Illumina Inc
  • LGC Biosearch Technologies
  • Merck Kgaa
  • Pacific Biosciences of California Inc
  • Perkinelmer Inc
  • Qiagen Nv
  • Takara Bio Inc
  • Thermo Fisher Scientific Inc
  • Trilink Biotechnologies Inc

The ongoing research in genomics due to the rise in chronic diseases, along with the advancement in genomics following the launch of new technologies, are driving the studied market on a growth path. Additionally, investments by manufacturers and governments in genomics are opening new avenues for the market globally.

Conversely, social and ethical issues relating to data privacy and the lack of professionals in developing regions impede the overall growth of the sequencing reagents market.

The global sequencing reagents market comprises the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.

Geographically, the Asia-Pacific is estimated to emerge as the fastest evolving region in the sequencing reagents market over the reviewed period. The region's robust growth can be attributed to the surging investments by government bodies across the major countries. Moreover, the increase in research and development of genomics is another factor contributing to the studied market's growth. For instance, the Indian government has introduced initiatives for startups in the biotechnology sector, which will ultimately foster the growth of the sequencing reagents market.

Key Topics Covered:

1. Global Sequencing Reagents Market - Summary

2. Industry Outlook

2.1. Impact of Covid-19 on Sequencing Reagents Market

2.2. Key Insights

2.3. Porter's Five Forces Model

2.4. Supply Chain Outlook

2.5. Market Attractiveness Index

2.6. Vendor Scorecard

2.7. Key Strategic Developments

2.7.1. Contracts and Partnerships

2.7.2. Business Expansions, Announcements, and Divestitures

2.7.3. Acquisitions & Mergers

2.7.4. New Product Launches & Developments

2.8. Market Drivers

2.8.1. Ongoing Research in Genomics Due to the Prevalence of Chronic Diseases

2.8.2. Advances in Genomics After the Launch of New Technologies

2.9. Market Challenges

2.9.1. Social and Ethical Issues Related to Data Privacy

2.9.2. Lack of Professionals in Developing Countries

2.10. Market Opportunities

2.10.1. Funding by Manufacturers and Government in Genomics

2.10.2. Growing Demand for Third-Generation Sequencing

3. Global Sequencing Reagents Market - by Application

3.1. Oncology

3.2. Clinical Investigation

3.3. Agri Genomics and Forensics

3.4. Reproductive Health

3.5. Other Applications

4. Global Sequencing Reagents Market - by Reagent Type

4.1. Sequencing Kits

4.2. Control Kits

4.3. Library Kits

4.4. Template Kits

4.5. Other Reagent Types

5. Global Sequencing Reagents Market - by Technology

5.1. Next-Generation Sequencing

5.2. Sanger Sequencing

5.3. Third-Generation Sequencing

6. Global Sequencing Reagents Market - by Industry Verticals

6.1. Research Institutes

6.2. Hospitals and Clinics

6.3. Pharmaceutical and Biotechnology Companies

6.4. Other Industry Verticals

7. Global Sequencing Reagents Market - Regional Outlook

8. Company Profile

9. Research Methodology & Scope

For more information about this report visit https://www.researchandmarkets.com/r/qc7wmk

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe